Key facts
- This page summarizes Laura Sepp-Lorenzino's Form 4 filing for Intellia Therapeutics, Inc. (NTLA).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 07 Jan 2025, 17:16.
Laura Sepp-Lorenzino - 03 Jan 2025 Form 4 Insider Report for Intellia Therapeutics, Inc. (NTLA)
- Reporting relationship
- EVP, Chief Scientific Officer
- Issuer ticker
- NTLA
- Reported as of
- 03 Jan 2025
- Net transaction value
- -$109,206
- SEC form
- 4
- Accepted by SEC
- 07 Jan 2025, 17:16:22 UTC
- Prior SEC filing
- 03 Jan 2025
- Next SEC filing
- 04 Jun 2025
- Source filing
- View source filing
- Reporting owner signature
- James Basta, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Laura Sepp-Lorenzino filed Form 4 for Intellia Therapeutics, Inc. (NTLA) on 07 Jan 2025.
Change
- Previous filing in this sequence was filed on 03 Jan 2025.
- Current net transaction value: -$109,206.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NTLA
transaction
Common Stock
Sale
- Transaction value
- $109,206
- Shares
- -8,966
- Change %
- -10%
- Price
- $12.18
- Shares after
- 77,388
- Date
- 03 Jan 2025
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2025, and does not represent a volitional trade by the Reporting Person.